Drug-induced QT interval prolongation: Clinical, safety and regulatory update

Current Drug Safety

Volumn 5, Issue 1, 2010, Pages 41-43

  Di Girolamo, Guillermo ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FAVALORO UNIVERSITY   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASTEMIZOLE; CARDIOVASCULAR AGENT; CISAPRIDE; FEXOFENADINE; GREPAFLOXACIN; NEUROLEPTIC AGENT; POTASSIUM CHANNEL HERG; PROKINETIC AGENT; QUINIDINE; TERFENADINE; DRUG;

DRUG SAFETY; EDITORIAL; GENDER; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; DRUG LEGISLATION; ELECTROCARDIOGRAPHY; FEMALE; GENETICS; MALE; RISK FACTOR;

ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LEGISLATION, DRUG; LONG QT SYNDROME; MALE; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; TORSADES DE POINTES;

EID: 77950839904     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610789869120     Document Type: Editorial

References (12)

1. Zünkler BJ. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther 2006; 112: 12-37.
2. Sanguinetti MC, Tristani-Firouzi M. HERG potassium channels and cardiac arrhythmia. Nature 2006; 440: 463-469
3. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-2790
4. Moss AJ, Zareba W, Benhorin J, et al. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol 2001; 6: 333-341
5. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride. Impact of food and drug administration regulatory action. J Am Med Assoc 2000; 284: 3036-3039
6. FDA U.S. Department of Health and Human Services Food and Drug Administration. The non-clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhyhmic drugs 2005.
7. ICH Topic S 7 B. The nonclinical evaluation of the potential for delayed ventricular repolarization QT interval prolongation by Human Pharmaceuticals. EMEA 2005.
8. ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. EMEA 2005.
9. Cavero I, CrumbW. Safety pharmacology society. Proceedings of the 5th annual meeting. Expert Opin Drug Saf 2006; 5: 181-185
10. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005; 28: 1009-1028
11. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 2006; 54: 116-129
12. Arizona Center for Education and Research on Therapeutics. Available from: http://www.azcert.org/